Recently, its reported that intrahepatic cell senescence strongly associated with the pathogenesis of liver diseases, such as steatohepatitis, liver fibrosis, and cirrhosis
Inflammatory Markers Chronic low-grade inflammation is a hallmark of obesity and metabolic syndrome
:
Building the Stack: Step by Step Step 1 [1] : Pre-Stack Assessment Before starting the stack, complete the following: Physician consultation (telehealth or in-person) Baseline labs: metabolic panel, HbA1c, lipids, copper/ceruloplasmin (if any copper metabolism concern) Baseline photos: face, abdomen, arms, thighs, and any areas of concern, taken in consistent lighting Health history review: screen for semaglutide contraindications (thyroid cancer history, pancreatitis, MEN 2) and GHK-Cu contraindications (Wilson's disease, copper allergy) Getting started Step 2: Start Semaglutide Begin semaglutide at 0.25 mg once weekly

As First-Line Treatment Guidelines increasingly support GLP-1 agonists as first-line treatment alongside or instead of metformin: When to consider first-line GLP-1: Established cardiovascular disease High cardiovascular risk Significant obesity (BMI 35+) Strong desire for weight loss Insurance coverage available Traditional metformin-first approach: Lower cost without insurance Decades of safety data Effective for many patients Can add GLP-1 later if needed For many patients, starting with a GLP-1 medication rather than metformin provides superior comprehensive benefit
Protects and supports cellular function